LILLE, France--(BUSINESS WIRE)--ImaBiotech will be conducting a pilot study with pharmaceutical company GlaxoSmithKline (GSK) on mass spectrometric derived imaging technology in the ADME and Toxicology fields. ImaBiotech, a leading service provider for MALDI imaging focuses on quantification challenges and volumetric imaging data interpretation via the development of specially adapted multimodal imaging methods and dedicated software, known as Multimaging™. Multimaging™, a new Advanced Technolo
| < Prev | Next > |
|---|
